Ricevi le ultime notizie sulle azioni Dermata Therapeutics con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di DRMA

Ultime notizie per

Dermata Therapeutics

Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics Inc

News

Press Releases

Dermata's XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks

Earnings

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments

Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18th

Life Science Virtual Investor Forum Agenda Announced for September 18th

Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025

Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing

Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office

ACUT

DRMA

DRMAW

HMTXF

INNMF

PETV

SIGY

TSXV:HEM

UEEC

Aditxt

Ainos

Apollomics

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

Azitra

Bone Biologics

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

BioVie

ETHZilla

GRI Bio

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

Liminatus Pharma

Lixte Biotechnology Holdings, Inc. - Warrants

Lixte Biotechnology

Medicus Pharma

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

Sunshine Biopharma

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

Shuttle Pharmaceuticals Holdings, Inc. - common stock

Shuttle Pharmaceuticals

Salarius Pharmaceuticals, Inc. - Common Stock

Salarius Pharmaceuticals

Silexion Therapeutics

Surrozen

Alaunos Therapeutics, Inc. - Common Stock

Comments

Dermata Therapeutics Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO